Results support the development of PLX-R18 for hematologic acute radiation syndrome (H-ARS), currently under a $4.2 million contract with the U.S. National Institutes of Health PLX-R18 has the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results